MCK

MCK

USD

McKesson Corporation Common Stock

$695.000+2.790 (0.403%)

即時價格

Healthcare
Medical Distribution
美國

價格圖表

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$692.210

最高

$695.630

最低

$681.920

交易量

0.11M

公司基本面

市值

87.1B

行業

Medical Distribution

國家

United States

交易統計

平均交易量

0.99M

交易所

NYQ

貨幣

USD

52週範圍

最低 $464.42當前 $695.000最高 $728.32

AI分析報告

最後更新: 2025年4月25日
由AI生成數據來源: Yahoo Finance, Bloomberg, SEC

MCK: McKesson Corporation Common Stock - Analyzing Recent Moves & What Might Come Next

Stock Symbol: MCK Generate Date: 2025-04-25 23:30:15

Let's break down what's been happening with McKesson stock lately, looking at the news, how the price has moved, and what some predictions are saying.

Recent News Buzz

The news flow around MCK has been mostly positive lately, especially from the folks who analyze stocks professionally. We saw a few big names – B of A Securities, Mizuho, and Morgan Stanley – all come out and say they like the stock. Not only did they keep their positive ratings (like "Buy" or "Overweight"), but they also bumped up the price they think the stock is worth in the future. B of A, for instance, raised their target price quite a bit, from $665 all the way up to $755. Morgan Stanley and Mizuho also lifted their targets, though not quite as dramatically.

So, the main vibe from the analyst community is definitely upbeat. They seem to think McKesson has more room to grow.

There was also news about Rite Aid potentially filing for bankruptcy again. Now, McKesson is a major drug distributor, and Rite Aid is a customer. This kind of news is something to keep an eye on because a customer having financial trouble could potentially impact a supplier like McKesson. However, the analyst upgrades came out after or around the same time as the Rite Aid news, and they were still positive. This suggests that, based on the information provided, the market might be focusing more on McKesson's overall strength or other business areas rather than seeing the Rite Aid situation as a major immediate threat to MCK's outlook. The dominant news signal here is clearly the analyst confidence.

Checking the Price Action

Looking at the stock chart over the past few months, MCK has been on a pretty solid upward trend. It started the year trading in the high $500s and low $600s. Fast forward to April, and we saw a significant jump, with the price hitting a peak around $728 early in the month. Since that spike, the stock has pulled back a bit and has been trading mostly sideways, hovering in the high $600s. The last reported price is $695.00.

So, the stock has made a big move up, and now it seems to be consolidating or taking a breather around this higher level.

What about the future? An AI model that looks at stock prices is predicting a slight upward movement over the next couple of days. It sees the price potentially moving up by a few percent. This aligns somewhat with the recent trend of holding onto gains after the big April jump.

Putting It All Together: Outlook & Ideas

Based on the analyst optimism, the stock's recent strong upward move (even with the recent pause), and the AI's short-term positive prediction, the situation for MCK looks generally favorable right now. The analysts raising their price targets tells us they believe the stock is undervalued even at these higher levels. The price chart confirms the stock has been strong, and the AI suggests that strength might continue in the very near term.

Given this picture, the apparent near-term leaning seems to favor potential buyers or those already holding the stock. It looks like there might be room for the price to climb further, especially if it can break out of this recent sideways trading range.

If someone were considering getting into this stock, the current price area around $695 could be a point to watch. It's right where the stock has been trading recently, and the AI prediction suggests it could move up from here. The recommendation data also pointed to potential entry points slightly below the current price, which could be interesting if the stock dips a little.

For managing risk, thinking about potential exit points is smart. If the stock continues its upward path, the recent high near $728 could be a level where some investors might consider taking some profits. The higher analyst targets, like $745 or $755, represent more optimistic views of where the stock could go over a longer period. On the downside, setting a stop-loss order is crucial to limit potential losses. The recommendation data suggested a stop-loss around $619.21. While that's quite a bit below the current price, it's a level that, if broken, might signal a significant change in the stock's trend. A tighter stop might also be considered depending on an individual's risk tolerance and investment horizon.

Company Context

It's helpful to remember that McKesson is a giant in the healthcare sector, primarily focused on medical distribution. They move drugs and supplies to pharmacies, hospitals, and other healthcare providers. This business model means they are deeply connected to the healthcare system's overall health and the dynamics of drug pricing and distribution. That's why news about pharmacies (like Rite Aid) or analyst views on the healthcare supply chain are particularly relevant to MCK's performance.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can go down as well as up. You should always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

相關新聞

Analyst Upgrades

B of A Securities Maintains Buy on McKesson, Raises Price Target to $755

B of A Securities analyst Michael Cherny maintains McKesson with a Buy and raises the price target from $665 to $755.

查看更多
B of A Securities Maintains Buy on McKesson, Raises Price Target to $755
Reuters

Rite Aid weighs repeat bankruptcy filing, WSJ reports

U.S. pharmacy chain Rite Aid is weighing a possible repeat bankruptcy after its recent financial restructuring failed to put the drugstore chain on a sustainable path, the Wall Street Journal reported on Friday.

查看更多
Rite Aid weighs repeat bankruptcy filing, WSJ reports
Analyst Upgrades

Mizuho Maintains Neutral on McKesson, Raises Price Target to $690

Mizuho analyst Steven Valiquette maintains McKesson with a Neutral and raises the price target from $630 to $690.

查看更多
Mizuho Maintains Neutral on McKesson, Raises Price Target to $690
Analyst Upgrades

Morgan Stanley Maintains Overweight on McKesson, Raises Price Target to $745

Morgan Stanley analyst Erin Wright maintains McKesson with a Overweight and raises the price target from $642 to $745.

查看更多
Morgan Stanley Maintains Overweight on McKesson, Raises Price Target to $745

AI預測Beta

AI推薦

看漲

更新於: 2025年4月27日 下午10:34

看跌中立看漲

69.6% 信心度

風險與交易

風險級別1/5
低風險
適合
保守
交易指南

入場點

$695.41

獲利了結

$733.16

止損

$625.31

關鍵因素

PDI 5.8 在 MDI 3.8 上方,ADX 18.1,表明看漲趨勢
當前價格非常接近支撐位 ($693.19),表明強勁的買入機會
交易量是平均值 (11,244) 的 5.8 倍,表明極強的買入壓力
MACD 0.5998 在信號線 0.6557 下方,表示看跌交叉

保持更新

設定價格提醒,獲取AI分析更新和即時市場新聞。